JAMA Submission Guide

JAMA is not a stronger version of a specialty journal. Editors are screening for four things simultaneously:

1. Clinical importance across medicine. The question must matter beyond one subspecialty. Interesting data without a broad practice consequence falls short.
2. Methodological discipline. Design quality, adequate sample size, follow-up strength, and generalizability all need to be visible on first read. A paper that sounds important but has visible analytical weaknesses will not survive initial statistical screening.
3. Package completeness. JAMA uses the submission package itself as a filter. The mandatory elements, structured abstract, Key Points (Question / Findings / Meaning in 75-100 words), Data Sharing Statement, and the matched EQUATOR checklist, are not just formatting. Weak Key Points or a vague Data Sharing Statement tell editors the manuscript is not ready for the general-medicine audience.
4. First-read clarity. Editors need to understand what changed and why it matters without digging through specialist framing. The title, abstract, and first figure or table should make the practice consequence obvious within 60 seconds.

Many technically solid papers fail because the work is good but the audience case is too narrow. If you removed the journal name, would the paper still feel like a general medical paper? If not, the fit problem is bigger than formatting.

Not every JAMA submission is an Original Investigation. Understanding which format fits your work prevents scope mismatch before you start.

Original Investigation is the primary research lane: 3,000 words, structured abstract, Key Points, up to 5 tables/figures, 50-75 references. This is where RCTs, large cohort studies, and definitive observational analyses land. The evidence bar is high, editors want studies that change practice, not just report associations.

Research Letter is shorter (600 words, 1 figure/table, 6 references) and suited for preliminary findings, novel observations, or replication studies that don't warrant full-length treatment. Research Letters still go through peer review, and they still need to matter to a general audience. Many authors underestimate this format's rigor.

Viewpoint (1,200 words, no abstract) allows opinion and analysis on topics relevant to medicine. It's invited or unsolicited, but unsolicited Viewpoints face steep competition. The argument needs to be timely, specific, and grounded in evidence, not a general commentary on a broad topic.

Review / Clinical Review articles are typically commissioned, but JAMA accepts proposals. These are comprehensive evidence syntheses aimed at clinicians who need an actionable summary. If your work would be better framed as a review, propose it explicitly rather than forcing it into the Original Investigation format.

JAMA operates within the JAMA Network, which includes 11 specialty journals (JAMA Cardiology, JAMA Oncology, JAMA Internal Medicine, JAMA Neurology, and others). This changes the submission calculus in two ways.

First, when JAMA's editors desk-reject a paper, they may offer a referral to the specialty journal they think fits better. Authors can also preselect referral during submission. This is not a consolation prize, JAMA Network specialty journals are well-ranked in their fields, and a referral can save months of resubmission time.

Second, this means your cover letter needs to anticipate the referral question. If your paper could plausibly go to JAMA Cardiology, explain in the letter why the general-medicine audience is the right one. If you can't make that case convincingly, the specialty journal might actually be the better strategic target.

The strongest JAMA cover letters sound like one editor helping another understand the paper. They should:

• define the clinical question in one sentence
• explain the practical or policy consequence in concrete terms
• argue why JAMA's general-medicine readership is the right audience, not why the journal is prestigious
• acknowledge the article type and explain why flagship JAMA (not a JAMA Network specialty journal) is the right venue

JAMA's instructions let authors preselect referral to a Network specialty journal if the flagship rejects. If the paper would obviously fit JAMA Oncology or JAMA Cardiology more naturally, the letter should not pretend otherwise. Editors notice when the cover letter is asking for prestige rather than audience fit.

Specialty paper dressed in broad language. If the paper mainly serves one subspecialty, no amount of general phrasing will change the fit. This is the single most common desk rejection reason.

Practical consequence is weak or overstated. Either the result doesn't change practice visibly enough, or the framing promises more than the evidence supports. JAMA editors are trained to spot both.

Key Points are vague. If the Question / Findings / Meaning summary doesn't make the practice change obvious, editors read that as the authors not yet knowing what the paper actually says.

Package looks operationally loose. Incomplete disclosures, soft checklist work, unstable Data Sharing Statements, or a structured abstract that reads like it was pasted in late. JAMA screens harder at the front door than most journals.

Design vulnerability is visible. Underpowered studies, too-local populations, or methodological gaps that the cover letter tries to explain away. Editors see those problems faster than authors expect.

Cross-document mismatches. JAMA requires manuscript word count on the title page, and the package has to be internally consistent across manuscript, checklist, protocol, and registry details. A trial registration that doesn't match the paper's primary endpoint, or a CONSORT flow diagram that conflicts with the methods section, gets noticed at the editorial stage. JAMA is one of the journals where cross-document inconsistency triggers rejection before scientific review begins.

Understanding the post-submission timeline helps set expectations and plan your response strategy.

Days 1-2 (editorial triage). Most JAMA submissions receive an initial editorial decision within 48 hours. The majority are desk rejections, often with a suggestion to consider a JAMA Network specialty journal. This is the fastest desk triage among the big four general medical journals.

Days 3-25 (peer review, if invited). Papers that pass the editorial screen go to 2-3 external reviewers. JAMA's median first decision with peer review is 25 days, faster than The Lancet or BMJ, comparable to NEJM. JAMA also uses dedicated statistical reviewers, which means your analytical approach will be examined by someone with specific biostatistical expertise.

Revision requests. If you receive a revise-and-resubmit, respond precisely. JAMA editors track whether revisions address every reviewer point. Do not introduce new analyses or findings not requested by reviewers, this resets the editorial clock and raises questions about the stability of the original work.

Days 43+ (acceptance to publication). Once accepted, the median time to online publication is 43 days. JAMA publishes accepted papers online before print, so your work becomes citable quickly.

• Is JAMA a Good Journal?
• How to Avoid Desk Rejection at JAMA
• JAMA Impact Factor
• Is BMJ a Good Journal?

Before you upload, run your manuscript through a JAMA submission readiness check to catch the issues editors filter for on first read.

In our pre-submission review work with manuscripts targeting JAMA, five patterns generate the most consistent desk rejections worth knowing before submission.

• Specialty paper with no visible general-medicine consequence (roughly 35%). The JAMA instructions for authors define Original Investigations as papers whose questions matter to physicians across medicine, and the journal's 4% research acceptance rate reflects how strictly that standard is applied. In our experience, roughly 35% of desk rejections involve manuscripts that present strong clinical research within cardiology, oncology, neurology, or another specialty without establishing a broader clinical consequence that would matter to a general physician. Editors specifically screen for manuscripts where the finding changes how a non-specialist physician thinks or acts, and papers that read as specialty papers with broad-significance language added consistently fail that screen.

• Key Points are vague or do not commit to a practice change (roughly 25%). In our experience, we find that roughly 25% of submissions arrive with Key Points (Question, Findings, Meaning) that summarize the study design or findings without committing to a specific, testable practice consequence in the Meaning field. In practice, JAMA editors treat weak Key Points as a signal that the authors have not yet resolved what the paper actually says to a general-medicine reader, because the Key Points format requires a practice-facing claim, not a cautious interpretation.

• Package looks operationally loose for the JAMA editorial screen (roughly 20%). In our experience, roughly 20% of submissions arrive with one or more package elements that look incomplete or unstable: a Data Sharing Statement that describes data availability in vague terms, an EQUATOR checklist that is partially completed, a structured abstract that reads like a specialist summary rather than a practice-facing argument, or a word count that significantly exceeds the 3,000-word limit. Editors screen for operational readiness before scientific merit, and packages with visible administrative gaps are consistently returned before reaching peer review.

• Practical consequence overstated beyond what the design supports (roughly 15%). In our experience, roughly 15% of submissions frame a definitive practice recommendation from an observational design, a single-site study, or a sample size that does not visibly support the strength of the conclusion. JAMA's statistical reviewers are embedded in the editorial process, and manuscripts where the abstract or conclusion language outruns the evidence package consistently attract statistical-review flags before external peer review begins.

• Cross-document mismatch between manuscript, checklist, and registry (roughly 10%). In our experience, roughly 10% of submissions contain a mismatch between the primary endpoint stated in the manuscript and the endpoint registered in the trial registry, a CONSORT flow diagram that conflicts with numbers in the methods section, or a STROBE checklist item that references a section the manuscript does not contain. JAMA's editorial system is specifically designed to detect these mismatches, and a cross-document inconsistency is treated as a package-integrity problem rather than a revision opportunity.

SciRev community data and Clarivate JCR 2024 bibliometric data provide additional benchmarks when evaluating submission timing.

Before submitting to JAMA, a JAMA submission readiness check identifies whether your general-medicine framing, Key Points, and package completeness meet the editorial bar before you commit to the submission.